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Abstract New health technologies are rapidly emerging from various areas of
bioscience research, such as gene editing, regenerative medicine and synthetic
biology. These technologies raise promising medical possibilities but also a range of
ethical considerations. Apart from the issues involved in considering whether novel
health technologies can or should become part of mainstream medical treatment
once established, the process of research translation to develop such therapies itself
entails particular ethical concerns. In this paper I use synthetic biology as an
example of a new and largely unexplored area of health technology to consider the
ways in which novel health technologies are likely to emerge and the ethical
challenges these will present. I argue that such developments require us to rethink
conventional attitudes towards clinical research, the roles of doctors/researchers and
patients/participants with respect to research, and the relationship between science
and society; and that a broader framework is required to address the plurality of
stakeholder roles and interests involved in the development of treatments based on
novel technologies.
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Introduction
For almost all areas of bioscience, one of the spheres of application that holds most
promise and interest is the potential to develop new therapies to improve human
health. The current biotechnological landscape features a proliferation of possibil-
ities for new health technologies from areas such as genomic and personalised
medicine, gene editing, reproductive technologies, stem cells and regenerative
medicine.
Ethical concerns associated with these technologies often attach to the social
consequences of their eventual widespread use: for human welfare and global health
equity; for our definitions of health, wellbeing and disease; even for our definition of
‘‘being human’’. These issues, however, are not the beginning of the story:
important questions arise even before these technologies reach the point of clinical
availability and wider health impact, in terms of what is required to develop
treatments to that point, and the ethical issues associated with the use of
experimental therapies and participation in clinical research.
Synthetic biology offers a particularly interesting example in this respect because
of its fluidity and ‘multipleness’ as a concept [10]: it encompasses a diverse range of
possible technologies while simultaneously functioning as an object of expectation,
‘‘the new technoscience’’, around which ‘‘socio-technical imaginaries’’ and
promises of future benefit, including better health, are built [1]. Given the extent
to which the field has been constituted around these possibilities, thinking about
synthetic biology as the focus of promissory narratives rather than as a single field
of research allows us to shift our attention from technology-specific concerns and
towards factors relevant to the social shaping of health innovation in general.
My aim in this paper is therefore to examine issues related to the development of
novel health technologies as experimental treatments, using the idea of synthetic
biology health technologies to illustrate features of the health innovation landscape
that require ethical attention. I start by identifying a number of factors to be taken
into consideration when thinking about the development of experimental treatments
and new therapies, focusing on ethical issues surrounding participation in clinical
research, and to the clinical use of experimental treatments (which may or may not
be the same thing, a point which I will return to discuss later). Considering the likely
pathways by which synthetic biology and other novel health technologies may
develop to the point of clinical application, and the problems that arise from this, I
argue that existing ethical approaches to clinical research participation may no
longer be appropriate to describe the relationships and interests of stakeholders in
this process: clinical translation in the contemporary setting poses concerns that
require us to rethink our ethical approach. I outline an alternative approach based on
conceptualising science as a social institution of public benefit, with the aim of
shifting ethical thinking and practice at the research translation interface.
Finally, on the basis of this, I will draw some tentative conclusions about the
conditions by which research into emerging technologies for human health and the
development of novel therapies should proceed and how it should be regulated. I
suggest that greater openness in relation to research, global cooperation with respect
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to research and to health care, and the mechanisms for accessing therapies are three
important facets that should be addressed.
Synthetic Biology and Health Technologies
Synthetic biology has been broadly described as ‘‘a field which aims to construct
living systems de novo’’ [10]. One manifestation of synthetic biology that has
received considerable public attention is the work carried out by scientists at the J
Craig Venter Institute, whose creation of a bacterium with a synthetic genome [25]
was widely reported as ‘‘the first artificial life form’’. Although this did not really
constitute ‘creating life from scratch’ as such [32, 50], the event served to bring
synthetic biology into the spotlight, including prompting an investigation and report
by the US Presidential Commission for the Study of Bioethical Issues [26, 47].
While this minimal genome synthesis research is a high-profile aspect of
synthetic biology, the field is broader than this. Its activities have been categorised
into three general approaches: engineering of modular biological parts that can be
combined into cellular systems for various purposes; cell engineering via genome
synthesis (including the Venter Institute work); and protocell creation [45]. These
diverse and varied endeavours are united by the aim of ‘engineering life’ or, as
scientists engaged in the field have described it, ‘‘the design and construction of new
biological parts, devices, and systems and the re-design of existing, natural
biological systems for useful purposes’’ [10]. Nevertheless, scholarship in science
and technology studies has highlighted the ways in which the ‘field’ of synthetic
biology resists clear definition, even as it emerges from a combination of certain sets
of practices, shared goals and epistemologies, networks of people and institutions,
and socio-political positioning [1].
Considerations of the ethical challenges posed by the potential application of
synthetic biology for human health therefore attach to the idea, more than the
everyday reality, of what synthetic biology ‘is’. While the possibilities for health
technologies from synthetic biology are myriad—for example new systems for drug
development and production; engineered biological circuits; biosensors; cell-based
therapies; microbiome engineering—it is the idea of synthetic biology as the focus
for socio-technical imaginaries that attracts concerns. In this regard, the concept of
‘‘synthetic’’ in the sense of ‘artificial’, in opposition to ‘natural’, has emerged
strongly as a feature of synthetic biology. Other key characteristics of synthetic
biology are the importance of design and engineering principles, whether it be in re-
designing existing systems and organisms or designing new ones ‘from scratch’; and
the idea of improving on nature through this process.
Each of these conceptual features gives rise to potential ethical issues:
Incorporating synthetic biology components into medical treatment could result in
hybrid humans whose bodies are a combination of ‘natural’ and ‘artificial’
biological components, which in turn might have implications for our understanding
of embodiment and its relationship to the ‘natural’ or ‘biological’. The reductionist
approach to biological systems might also prompt us to ask whether ‘humanity’ is
something that can or should be designed or engineered, or whether something is
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lost in the apparent reduction of life to machine [17, 19, 33]. Another possible
consequence of synthetic biology therapies is that, as for other forms of regenerative
medicine, they might have the potential to cure or repair our bodies to the point of
being ‘better than well’ [22]. This of course invokes questions related to the ethics
of human enhancement, including the expanding boundaries of what is considered
to be disease, what is in consequence viewed as therapy, and hence the ‘moving
goalposts’ of medicine.
Analysis of these complex issues will need to take into account the construction
of moral concepts in relation to biology, for example how concepts such as
‘synthetic’ and ‘natural’, rather than being immutable categories, are actively
constituted, negotiated and re-valued through scientific practices and in relation to
scientific ideals [10].
My concern in this paper, however, is not with these further-off questions about
the eventual use of synthetic biology health technologies once developed, but in
using the ‘imaginaries’ of synthetic biology to scrutinise more closely the process of
research translation, from the promises generated by bioscience innovation, to the
testing of potential new therapies, and how and to whom these emerging treatments
are made available.
Developing Synthetic Biology Therapies: Some Possibilities
The ways in which new health technologies are currently emerging reveal social
trends and attitudes to novel treatments that allow us to speculate about how
synthetic biology therapies might developed. By this I mean not speculation
regarding the technological or scientific possibilities, but an exploration of the
factors that are likely to drive the process of development and influence the
reception of these therapies. Health technologies such as stem cell treatments and
genomic testing that are presently in the transition stage between novel
experimental therapy and standard medical treatment provide us with models for
how new fields of research can translate from the laboratory to the clinic and
highlight potential problems, while established models such as the pharmaceutical
industry also highlight relevant factors that may influence future health innovation.
Thinking about likely scenarios in relation to the evolution of synthetic biology
treatments will help to identify factors that characterise the landscape of health
innovation, before proceeding in Part 4 to explore the implications and issues raised.
Addressing these issues will uncover underlying ethical tensions that not only may
arise with respect to the future development of synthetic biology therapies, but are
also relevant to the health technologies of today.
Synthetic biology health technologies, then, are likely to:
… be sought-after by patients Synthetic biology therapies may offer the
possibility of new and more effective treatments for disease, or even therapies for
previously untreatable conditions (not to mention their potential for enhancement
uses). As such, they will be desirable to some even at the experimental stages.
Patients suffering from the burden of chronic disease that can be only
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incompletely relieved with current treatments, or those for whom no other
treatment option is available, or those for whom experimental treatment may be a
last-ditch attempt: all of these are situations in which people may wish to avail
themselves of emerging treatments even if not yet fully established. The rapid
growth of the ‘‘stem cell therapy’’ industry [36, 38, 49] whereby numerous clinics
around the world are ‘‘exploiting patients’ hopes by purporting to offer effective
stem cell therapies for seriously ill patients, typically for large sums of money,
but without credible scientific rationale’’ [30], is evidence of a large unmet
demand for new therapies.
Whether novel treatments either will or should be made available in such
circumstances of demand, and under what conditions, is a matter that requires
careful consideration. The role of marketing in promoting new health technolo-
gies and making them attractive to the public is another element that cannot be
ignored and that comes into play particularly when commercial interests are
involved. Both of these issues will be discussed further below.
… involve different types of risk The clinical research needed to develop
synthetic biology health technologies may require a different approach to
assessing and managing risks. Because of the range of technologies encompassed
by synthetic biology, the possible risks are diverse in nature, as well as level and
scope. For example, treatments that make use of engineered micro-organisms
may have effects not just for individual patients, but at environmental or
population level. Additionally, due to the relative novelty of synthetic biology as
a field of science as well as its application to health care, the risks involved
represent something of a qualitative as well as quantitative unknown: there will
be uncertainty over not only the likelihood but the nature of potential adverse
effects. This may have consequences for how we should approach such
technologies at the clinical research stage and in the long-term.
… develop at different rates across countries The pace at which synthetic biology
therapies are developed, tested and become available is unlikely to be a uniform
one, internationally (and even nationally) speaking. Transnational differences in
research capacity and in particular the regulation of research and health care will
most probably lead to differential rates of progress with respect to the
development of therapies, and to discrepancies in the local availability of
treatments once established. That this is already the case with respect to virtually
every other health technology is evident merely by reference to differing
standards of global health care, as well as with respect to more specialised
technologies and the phenomenon of medical tourism produced by discrepancies
in treatment availability between regions [18].
These differences will mean that both at the experimental stage and later, access
to synthetic biology therapies will likely vary amongst countries, with treatments
being available in one country but not another. Research would also be unevenly
distributed; however, increased local research contribution would not necessarily
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correlate with increased local availability of treatments. This raises a number of
important ethical problems in terms of global justice and transnational regulation
of health technologies, as will be discussed below.
… be driven partly by commercial concerns Commercialisation has become an
integral part of the biotechnology innovation pathway. While there may still be
particular instances of health technologies that are developed primarily through
public research, very few if any fields of biomedical science are completely
devoid of commercial interests. Synthetic biology is no exception: already the
push to secure patent rights over various aspects of the technology has begun,
sparking debate as to what the effects of intensive patenting in this area are likely
to be, and whether the current patent system is in fact an appropriate or optimal
mode of managing intellectual property in this area of research [9, 13, 52].
As synthetic biology research progresses towards clinical application, we can
expect to see further debates over intellectual property rights, similar to those
currently occurring in the areas of stem cell research [42, 49], genetic testing
[16, 59] and gene editing [58]. There are likely also to be consequences for how
these technologies are made available to the public, in terms of access and cost;
and how they are made desirable to the public, particularly through marketing,
both direct and via the health care system.
Issues of Concern
The features of the probable developmental pathway for synthetic biology health
technologies as outlined above give rise to a number of particular concerns. While
none of these are unique to synthetic biology, together they highlight what I would
argue is an overall need to reconsider the ethical paradigms that apply to clinical
research and experimental treatment, and to science and medicine in general, in
prospect of the emergence of new health technologies including synthetic biology
treatments.
Transnational Challenges and Synthetic Biology Tourism
Transnational discrepancies in the regulation of research and health care and hence
the availability of treatments at the early stages of development are likely to result in
both health and research tourism with respect to synthetic biology technologies.
A textbook case for this in recent times is embryonic stem cell research, the
moral controversy over which has produced an international patchwork of
regulation ranging from the highly restrictive to the permissive, and in some cases
still no regulation at all [31]. In the case of stem cell science, transnational
discrepancies in policy have led to research tourism, regulatory uncertainty and
problems for international scientific cooperation [31, 41, 43]. While the ethical
issues and consequent regulatory concerns associated with synthetic biology have
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not (so far) polarised public opinion to quite such an extent, it is likely to be
differences in the regulation of health care research and clinical trials, rather than
basic research, that come to bear in this case.
Health care, provision of medical treatment and experimental therapies, and
clinical research are much more tightly regulated in some countries than others, and
this will open up disparities as synthetic biology therapies begin to emerge. If
regulations are too restrictive (or perceived as such) in one jurisdiction, scientists
and biotech companies may simply relocate their research activities to another,
more permissive jurisdiction. This will have economic and political implications:
concerns over falling behind on the scientific front and the loss of economic value to
local biotech industry will be juxtaposed against potential ethical objections and
concern for proper regulation. Issues may also arise with respect to how the benefits
of research are or should be made available: missing out on the research may mean
reduced access to its fruits, but on the other hand, to reap the benefits while avoiding
the ethical and resource burdens of carrying out the research creates problems of
justice and even complicity.
Further complexities emerge when clinical research is carried out across national
boundaries, a situation that is facilitated and encouraged by transnational regulatory
differences—when, let us say, the knowledge base, research capacity and economic
investment belong to one country, but the clinical trials are conducted in another.
This problem has received most attention in the context of cross-border research in
the developing world (see for example [2, 20, 23]), but the issues it creates do not
fall out solely along the so-called North–South axis.
Health tourism is another, though not unrelated, phenomenon that can create
regulatory and ethical dilemmas [18]: if treatments are not available in one place,
whether because of resource limitations or regulatory obstacles, people will seek to
travel elsewhere to obtain them. This may have ramifications for local health care
systems if unexpected side-effects or adverse consequences of ‘rogue’ treatments
subsequently require medical attention. On the other hand, if a treatment is showing
signs of success but has not yet been approved in a given country, or is unavailable
for other reasons, then to allow access only to those who can afford to travel
elsewhere to receive treatment creates potential problems of justice. This type of
situation is already emerging with respect to stem cell therapies, where medical
tourism has been identified as a phenomenon of concern [21, 40, 53], as well other
health technologies including reproductive medicine [5, 46] and assisted dying [44]
(if the latter can be classed as a ‘health technology’, that is).
To address the issues of both research and health tourism in relation to new
health technologies, a concerted effort towards global cooperation will be required
from policy-makers and from the scientific and medical community. This need not
mean complete regulatory harmonisation—indeed, complete harmonisation may not
be the best way to serve diverse global populations with differing health needs—but
at the very least, an awareness of the international context and the effects of local
regulatory and technological developments is necessary.
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Commercialisation and Consumerism
The almost inevitable involvement of commercial interests in the development of
synthetic biology therapies will have far-reaching consequences. One, highly likely,
is that in order to protect commercial interests, some may seek to assert intellectual
property rights over various aspects of synthetic biology research.
The effects of IP, particularly the patent system, on scientific progress and access
to innovation have been much-discussed [35, 59], and these issues are likely also to
apply in the case of synthetic biology. Without recapitulating these debates,
however, there is another aspect of commercialisation which merits discussion: the
expectation of profit as an incentive for research into synthetic biology therapies
creates pressure to ensure a receptive market for these therapies. Such pressure will
encourage the active marketing of synthetic biology health technologies, which will
in turn influence public expectations, understanding and attitudes towards these
technologies and synthetic biology in general. This will have a profound effect on
how research is driven and how participant interactions with technology are
mediated—for example, through the health care system, by biotech companies or by
patient lobby groups.
One scenario that might conceivably occur is the direct-to-consumer (DTC)
marketing of new synthetic biology therapies. In the context of genetic testing, DTC
provision has been a source of ongoing ethical consideration [28, 29]; DTC
marketing of stem cell therapies has likewise provoked recent concerns [36].
Similar issues would arise if DTC synthetic biology therapies became a reality.
Some of the fears about DTC health technologies relate to availability without
oversight: unregulated provision means that harms may be more likely to result and
risk cannot be managed effectively. For synthetic biology therapies, this would echo
concerns expressed about synthetic biology research and ‘backyard bioengineering’
or ‘DIY science’ [47]: a coordinated approach is necessary, to health applications as
well as research.
Another risk is that public expectation, assisted by profit-driven marketing, may
outpace the reality and the actual therapeutic capacity of the technology. Again, the
development of stem cell therapies aptly illustrates this possibility [36, 49]. This
may lead to nothing worse than disappointment and public disillusionment with
synthetic biology if promised outcomes fail to manifest—indirectly harmful
nonetheless, as the erosion of public trust in science will have long-term adverse
consequences for science and society alike. Alternatively, however, it may result in
direct harms ranging from mild to serious, if hopeful patients are led to squander
money on ineffective treatments, or if inadequately-tested treatments pose a danger
to health and life.
In either case, allowing profit to be a major driver of synthetic biology health
research will almost certainly have knock-on effects on users’ understanding of the
underlying science, the risks involved, the implications and their expectations of
successful therapy. Commercial pressures on technology will thus change the
relationships between developers, providers and users of synthetic biology therapy,
as well as the terms under which people may choose to take up these treatments.
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While this is not to say that commercialisation ought to be avoided altogether, an
awareness of these factors is crucial and their effects must be carefully scrutinised.
Risk and Access to Experimental Therapies
We noted previously that synthetic biology therapies may involve a different kind of
risk to that usually encountered in clinical research, due to the diversity and novelty
of the technologies involved, but that they will also be desirable to some despite
this. As synthetic biology therapies enter the testing phase, patients may wish to
enter trials in order to have the chance of receiving potentially beneficial new
treatment. This raises a broad problem of clinical research and medical ethics: under
what conditions should patients be given treatments that are still at the experimental
stage, even at their express request? Or, to cast it in another light, under what
conditions should willing volunteers be permitted to take part in clinical research?
The range of circumstances under which patients might wish to take part in trials of
synthetic biology therapy, or to receive experimental treatments, might be broader
than the range of circumstances under which medical practitioners are able to
administer treatment, or researchers able to admit them to trials.
Clearly it would be nonsensical to say that patients should be entitled to receive
whatever treatment they demand, or any volunteer, no matter how unsuitable,
should be included in a clinical trial. It is also the case, however, that not all of the
limitations on the availability of experimental treatment and the exclusion criteria
for clinical trials necessarily serve the interests of doctors or patients, researchers or
participants, medicine, science or the public: some may instead be directed at
limiting liability, avoiding negative press or expediting the progress of a therapy to
market [15, 60]. In a situation where a patient/participant is willing to take part in
research, a clinician judges that it might be in their medical interests to undergo the
procedure or receive the treatment, and scientifically useful information may be
gained, what reasons are there to prevent this taking place? How much risk, and
what uncertainties with respect to risk, should be tolerated, and who should decide
this? When taken in combination with the possibility of not only health and research
tourism but research participation tourism, the issue of access to experimental
therapies and participation in clinical research becomes more pressing.
The mitigation and management of risk becomes an important factor in this
regard, and one that invokes societal-level considerations of regulation and
mechanisms of ethical research governance. It is not only individual patients/par-
ticipants and clinicians/researchers who are involved in decisions over experimental
treatment, but policy-makers who set guidelines as to what sorts of research is
permitted and ethics committees who interpret these guidelines. Addressing this
issue thus requires us to consider, in addition to the roles and relationships of
individual actors in specific cases or circumstances, the relationship between
science and society and how this is mediated through the regulation and governance
of research.
I and others have argued elsewhere, taking the example of cancer drug trials
[15, 60], that ethical attitudes towards participation in ‘risky’ research may be overly
paternalistic and skewed in favour of ‘protecting’ potential participants. Although
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great emphasis in research ethics is placed on informed consent, autonomy and
voluntary choice, there are many potential trials in which patients are never given the
chance to consent and cannot exercise any autonomy to make a choice about taking
part, because the research is not permitted or would not receive ethics approval. Thus
participants’ autonomy is respected as far as saying ‘no’, but not as far as saying
‘yes’—an inherent asymmetry in the paradigm of research ethics.
If we are going to uphold, on the basis of respect for autonomy, the right of
individuals to refuse to take part in research for whatever reason (no matter how
irrational or against their medical interests) then we ought also to consider whether
respect for autonomy might also support some sort of right to be included. At the
least, respecting autonomy in relation to research should prompt us to consider a
role for potential participants to have some input into the research process and into
decisions over what sorts of research should go ahead—to be part-owners and active
stakeholders in research. We must also ask what levels of knowledge and
engagement are necessary for participants to be able to exercise genuine autonomy
as active co-producers of research, rather than passive subjects; and in turn what
will be required to achieve this.
Discussion
The issues identified above are not discrete but are interlinked aspects of a changing,
sometimes ill-charted technosocial landscape. Together, they suggest that a broader,
more joined-up approach to ethics across health care, clinical research, biomedical
science and biotechnology is required to deal with the health technologies that are
emerging at the intersection of these areas, including synthetic biology. Before
discussing how this might be achieved, I wish to address one further issue that also
highlights the need for a new approach.
Clinical Research or Experimental Treatment?
‘‘I continue to be astounded by how little the medical profession knows about my
condition. I guess that’s why they call it the practice of medicine’’ [24], at 105.
Thus far, in discussing the transition phase of synthetic biology therapies from
laboratory to clinic, I have considered clinical research and experimental treatment
together, and although distinguishing the two by the use of different terms, I have
not examined whether there may be material differences in the ethical implications
of each. I noted earlier, however, that this was an issue remaining to be resolved: are
experimental medical procedures and clinical research the same thing or not? The
problems of ethics and regulation encountered in this ‘grey area’ might also be
tractable to a different way of thinking about biomedical research and health care, as
aspects of the same broader enterprise.
Research and treatment are often regarded as different kinds of activities, subject
to different ethical norms [37]. In general, innovative treatment is characterised as
health care and the (medical) best interests of the patient are the dominant
consideration, whereas the focus in clinical research is much more on informed
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consent as the keystone of ethical practice—sometimes to the exclusion of other
considerations such as harm [55]. But why should this be so? What is it about the
research context that warrants this shift in ethical approach and underlying
assumptions? When does a novel therapy cross the line between research and
treatment—science and medicine—and where is that line to be drawn?
There is an argument for considering medical practice and medical science as
aspects of the same endeavour [34]. Conceptually, the difficulty of separating one
activity from the other perhaps indicates that they are not so different, while logically,
there is little to indicate why they should be. Even areas of established medical
practice can have an investigative aspect or lead to new scientific insights: recent
moves, for example, towards making patient health information available for research
purposes illustrate that data gathered in the context of medical practice can be of
immense value for medical science. And of course one of the ‘side effects’ of taking
part in research trialling new therapeutic agents is that the treatment might actually
work! That is to say, participation in research can be of direct therapeutic benefit to the
participant. Certainly this is not always going to be the case, and caution is needed to
manage possible misconceptions on the part of would-be patients. The possibility of
medical benefit from research participation is, however, if not a secondary aim then at
least not an unforeseen consequence of clinical research.
This argument gains further purchase when we consider the factors outlined
above. Consider the person attending a health care clinic who hears about a new
form of therapy privately available from a biotech company, decides to pay for the
treatment that is then administered by her doctor, but allows health monitoring and
data collection for research purposes. Is she a patient, a research participant, a
consumer or all three?
The problem of distinguishing research from medical treatment illustrates that
end-users have multiple roles with respect to technology: patient, participant,
consumer. In some ways this is not a new thing—but the current manner in which
new health technologies (including synthetic biology) are emerging intensifies the
ethical tensions produced by this plurality of roles, and the multiplicity of
stakeholder interests. The blurring of distinctions between research and treatment
and the increasing integration of these activities within the health system requires
new modes of ethical and regulatory thinking [34].
With respect to research participation, for example, we should allow that many
would-be participants will be motivated by benefit as well as beneficence. To take
adequate account of this, we need a conceptual framework for the ethical
governance of research that acknowledges and supports participants’ interests not
only in being protected from possible harms caused by the use of treatments at the
experimental stage, but in receiving the benefits that such treatments might also
produce. At the same time this framework must recognise the value of the
information gathered in the course of administering such treatments at all stages of
development: not just at the clinical trials phase but through what might usually be
deemed ‘experimental treatment’ and even beyond, as such therapies enter the realm
of standard medical practice. It should therefore recognise and support the public
interest, and the interests of scientists and future patients, in making such
information available for research use.
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A Conceptual Approach to Science Ethics and Research Translation
I have argued that to meet the challenges posed by the emergence of synthetic
biology health technologies there is a need for a paradigm of science ethics that can
support new ethical understandings of clinical research, the practice of medicine, the
roles of researchers/clinicians and participants/patients and the relationship between
science and society, as they are likely to evolve with respect to emerging health
technologies. While to describe the elements of a possible framework in detail is
beyond the scope of this paper, I outline here an approach that may provide a
foundation for further development.
Central to this broad approach to science ethics is an understanding of science as
a social institution that is of public benefit. In characterising science as a public
good and an institution that is constituted and supported by society, I hope to
suggest a moral perspective on science that can incorporate research ethics, medical
ethics and bioethics alike and allow consideration of both individual and societal
concerns. A few of the implications of this approach would be as follows:
If science is a public institution, scientists should perhaps be regarded as public
officers who have broad social responsibilities with respect to their field of
endeavour. Failures of social responsibility should be viewed in the same light as
breaches of scientific integrity, both being derelictions of a scientist’s public duty.
Giving scientists the responsibility and the opportunity to be stewards of their own
specialised knowledge for the public’s benefit may be an effective way of
addressing some of the problems associated with regulation of science and
biotechnology: for example, scientists are among the best-placed to promote global
cooperation and transnational harmonisation of health technologies at the exper-
imental stage.
Lest it seem that this interpretation of the nature of science places too heavy a
burden of responsibility on scientists, the public also have corresponding duties with
respect to the social institution of science. It has been argued elsewhere [11, 27, 51]
that research participation, and supporting science through participation, may be a
moral obligation. Others have contested this, particularly with respect to what
constitutes a moral obligation or duty [6–8, 56], but the thrust of the original
arguments is that, even if it falls short of an obligation, participating in research is
something that is ‘good to do’. This makes sense if we consider science as a whole, not
just individual research projects, to be a public good and a valuable social institution
[12, 14].While any sort of compulsion, even a weakmoral one, to take part in research
seems antithetical to current principles of research ethics, the notion may be more
amenable if we understand it as a more democratic duty to participation in research
broadly construed: not just to be an experimental test subject but to support, contribute
to and have a say about research. Fulfilling this obligation would also entail a duty to
be informed and to engage actively with science.
Might the same understanding of science as social institution and research as a
partly democratic social process in addition support a right (also broadly construed)
to participate in research? In the context of experimental treatments, the recent turn
towards the language of rights and rights-based claims as attempts to gain access to
treatment may be considered ethically problematic: for example, recognising and
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granting an unfettered ‘right-to-try’ in relation to experimental treatments might
have rather undesirable and unethical effects on patient and public health, and on
health technology innovation.
Rather than focusing solely on access to the end-products of science at the later
stages of clinical innovation, however, we should take a wider view of what
constitutes research for the purposes of understanding a right to participation. Once
again, stem cell science provides an illustration: in the turbulent environment of
market-based supply of innovative therapies and health consumer demand, scientists
warn that giving into what they see as unreasonable and ill-founded demands by
patients will lead to exploitation and harm [3, 4, 39]; patients, meanwhile, have
developed a deep mistrust of the dominant institutions of science and mechanisms
for therapeutic innovation, from which they feel excluded [54]. Is it perhaps a lack
of opportunities for democratic participation and engagement with both basic and
clinical research, upstream as well as downstream, and with the governance of
science and innovation, that has led to this impasse?
A right to participate in research broadly conceived, therefore, would not imply a
right to receive whatever experimental treatment one desired or to compel scientists
to conduct whatever research we might want to take part in, but rather a right to take
a more active role in research than the current, very limited, right only to refuse
what is offered us. We might, indeed, view both the right and the duty to participate
in research as an aspect of scientific citizenship, and in exercising that right and
fulfilling our civic duty, we would become active participants rather than passive
subjects.
Lastly, the public interest in science and the rights and duties that flow from this
rely on the assumption that research and the fruits of research will be used for public
benefit. As we know, however, this is not always the case, particularly when it
comes to private profit-driven science. The privatisation of science should therefore
be looked upon with the same scepticism as the privatisation of other services seen
as essential to a functioning society. Properly managed, public/private partnership in
science can promote efficiency to mutual benefit, but we must be vigilant of
allowing private interests to subsume those of the public.
Conclusions: Science Ethics and Research Translation
In this paper I have identified some ethical issues that may arise in the course of
development of synthetic biology therapies as an example of novel health
technologies, and argued that a new, broader framework for science ethics may
be necessary to deal with the challenges that synthetic biology therapies and other
emerging health technologies will present. I began by speculating about the possible
future evolution of synthetic biology therapies; I will conclude by briefly stating
some thoughts to bear in mind as we attempt to guide this evolution. Based on the
challenges identified and the account of science outlined above, the following are
some of the areas that require most pressing attention:
To overcome potential problems of health and research tourism that may result
from transnational regulatory and research differences, global cooperation will be
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required. An important factor in achieving this will be the power of scientists and
the international scientific community to set internal standards of conduct and to
instigate their own procedures to maintain these, and they have a responsibility to
society to do so.
Access to synthetic biology therapies at stages from early experimental to
established treatments will remain a possible source of contention. The interplay of
commercial, individual, public and scientific interests here creates complex ethical
tensions that will need to be resolved in order to shape synthetic biology research
and innovation in the way that most serves the public interest. In particular, the
potential effects of commercialisation to limit access and to sway societal attitudes
to synthetic biology therapies, neither in ways necessarily conducive to public
benefit, must be carefully assessed, and mechanisms to ensure appropriate access
(and discourage inappropriate access) to technology emplaced.
Finally, in relation to all aspects discussed: global cooperation, access to the
benefits of technology, and the factors that influence public opinion and
understanding of synthetic biology, strategies for promoting greater engagement
and openness with respect to research will need to be developed. Knowledge, as
well as application, is a product of science and therefore should be made available
and used for public benefit; and in order to make informed decisions about health
technology and to engage adequately as scientific citizens, members of the public
must have access to the information needed to develop an understanding of the
science. Transnational sharing of knowledge capital will also help to promote global
scientific cooperation and achieve greater parity in synthetic biology research. The
principle of openness and the concept of scientific knowledge as a public good, to be
shared for public benefit, should guide our ongoing considerations in this regard,
both with respect to synthetic biology therapies and basic research.
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